Related Experiment Videos
Nitric oxide (NO) and obstructive sleep apnea (OSA)
James S J Haight1, Per Gisle Djupesland
1Department of Otorhinolaryngology, St Michael's Hospital, University of Toronto, Toronto, Canada. haight@globalserve.net
Sleep & Breathing = Schlaf & Atmung
|July 16, 2003
Summary
Obstructive sleep apnea involves impaired nitric oxide (NO) transport to the lungs, affecting breathing regulation. This NO deficiency may contribute to short-term arousals and long-term cardiovascular complications like hypertension and stroke.
Area of Science:
- Physiology
- Sleep Medicine
- Cardiovascular Science
Background:
- Obstructive sleep apnea (OSA) is characterized by recurrent upper airway collapse during sleep.
- Nitric oxide (NO) plays a crucial role in vascular and respiratory regulation.
- The interplay between NO and OSA pathophysiology is not fully understood.
Purpose of the Study:
- To elucidate the critical role of nitric oxide (NO) in obstructive sleep apnea (OSA).
- To describe how impaired NO transport impacts respiratory control and sleep.
- To explore the potential link between NO deficiency and OSA-related complications.
Main Methods:
- Conceptual review integrating physiological mechanisms of NO in respiration and circulation.
- Analysis of NO's role in pharyngeal dilator muscle function and respiratory drive.
- Examination of NO's involvement in arousal regulation and its substrates.
Main Results:
- OSA can be defined by the intermittent failure to deliver nasal NO to the lungs, disrupting ventilation-perfusion matching.
- NO is essential for efferent pathways controlling the balance between inspiratory efforts and airway collapse.
- Recurrent arousals in OSA consume NO, and chronic NO deficits may stem from hypoxia, impacting cardiovascular health.
Conclusions:
- Nitric oxide (NO) is intrinsically linked to obstructive sleep apnea (OSA) pathophysiology.
- Impaired NO availability due to OSA contributes to both acute sleep disturbances and chronic cardiovascular disease.
- Restoring NO homeostasis may be a therapeutic target for managing OSA and its sequelae.